Ribosome Biogenesis and cell cycle regulation: Effect of RNA Polymerase III inhibition by Onofrillo, Carmine
Alma Mater Studiorum – Università di Bologna 
 
 
 
DOTTORATO DI RICERCA IN 
 
Oncologia e Patologia Sperimentale 
Progetto Nr.1 : Oncologia 
 
Ciclo XXV 
 
Settore Concorsuale di afferenza: 06/A2 
 
Settore Scientifico disciplinare: MED/05 
 
 
TITOLO TESI 
 
Ribosome Biogenesis and cell cycle regulation: 
Effect of RNA Polymerase III inhibition 
 
Presentata da: Carmine Onofrillo 
 
 
 
 
 
               Coordinatore Dottorato                                       Relatore 
 
                           Chiar.mo                                                   Chiar.mo 
                  Prof. Sandro Grilli            Prof. Massimo Derenzini 
 
 
 
 
 
Esame finale anno 2013 
            
2 
 
Index: 
   Relations  hip between cell growth and  
  Cell cycle progression.................................................. 5  
 
1 Aim of the thesis.............................................................  6 
 
2 Introductions............................................................... 7                                                                                   
    2.1 Cell Cycle............................................................... 7  
          2.1.1 Cell cycle control by  
                     CDK/Cyclin system........................................... 7 
           2.1.2 Cell Cycle checkpoints...................................... 12 
    2.2 The tumor suppressor P53 .................................... 15  
           2.2.1 P53 protein structure......................................... 15 
           2.2.2 P53 transcriptional target genes.......................... 18 
           2.2.3 MDM2 mediated P53 regulation......................... 21 
    2.3 Ribosome Biogenesis........................................... 23 
          2.3.1 The Nucleolus................................................. 24 
              2.3.2 Ribosomal RNA maturation  
                        and Ribosome subunit production................... 26 
   2.4 Modulation of cell cycle regulators and  
         control of ribosome biogenesis............................. 31 
   2.5 Ribosome biogenesis alterations effects  
        on nucleolar morphology  
        and cell cycle progression...................................... 34     
             2.6 RNA Polymerase III and Non coding RNAs......... 37 
          2.6.1 Enzime structure  .....................................37 
         2.6.2 RNA Polymerase III products..............................39 
3 
 
3 Results. ........................................................................ 43 
   3.1 POLR3A interference led to inhibition  
         of RNA Polymerase III activity ............................ 43 
   3.2 RNA Polymerase III inhibition  
         caused nucleolar fragmentation  
           and affects rRNA maturation.............................. 45     
   3.3 The ribosomal stress and nucleolar disruption  
         induced by RNA Polymerase III inhibition  
           did not activate the p53 pathway......... ..............47    
   3.4 RNA Polymerase III inhibition led to a p53    
          independent cell cycle arrest................................ 49    
   3.5 TF3A interference led to a specific  
         inhibition of 5S rRNA transcription ...................... 50     
   3.6 The lack of 5S rRNA is linked with  
         an altered RNA processing .................................... 52   
   3.7 5S rRNA depletion did  
         not activate p53 pathway ....................................... 53    
   3.8 TFIIIA inhibition caused  
         a P53 independent   cell cycle  arrest .................... 53 
 
4 Discussion ................................................................... 56 
 
 
 
 
 
4 
 
        5 Materials and Methods............................................... 60 
   5.1 Cell lines, culture conditions  
         and drug treatments............................................... 60     
   5.2 RNAi, plasmids and  
         transfection reagents............................................. 60     
   5.3 AgNOR staining .................................................... 61 
   5.4 RNA extraction, reverse  
         transcription and real-time qPCR.......................... 61 
   5.5 Analysis of newly synthesized rRNA  
         with 
3
H-Uridine labeling....................................... 63      
   5.6 Polysome profile................................................... 64   
   5.7 Western blotting.................................................... 64 
   5.8 Immunocytochemistry.......................................... 65 
   5.9 Cristal Violet Staining........................................... 66 
 
         6  References ................................................................... 67 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Ribosome Biogenesis and cell cycle regulation: 
Effect of RNA Polymerase III inhibition 
In cycling cells positive stimuli like nutrient, growth factors and mitogens 
increase ribosome biogenesis rate and protein synthesis to ensure both growth and 
proliferation. In contrast, under stress situation, proliferating cells negatively 
modulate ribosome production to reduce protein synthesis and block cell cycle 
progression. The main strategy used by cycling cell to coordinate cell proliferation 
and ribosome biogenesis is to share regulatory elements, which participate directly 
in ribosome production and in cell cycle regulation. In fact, there is evidence that 
stimulation or inhibition of cell proliferation exerts direct effect on activity of the 
RNA polymerases controlling the ribosome biogenesis, while several alterations 
in normal ribosome biogenesis cause changes of the expression and the activity of 
the tumor suppressor p53, the main effector of cell cycle progression inhibition  
(1. Montanaro L. et al., 2012). The available data on the cross-talk between 
ribosome biogenesis and cell proliferation have been until now obtained in 
experimental model in which changes in ribosome biogenesis were obtained either 
by reducing the activity of the RNA polymerase I (Pol I) or by down-regulating 
the expression of the ribosomal proteins. The molecular pathways involved in the 
relationship between the effect of the inhibition of RNA polymerase III (Pol III) 
activity and cell cycle progression have been not yet investigated. In eukaryotes, 
RNA Polymerase III is responsible for transcription of factors involved both in 
ribosome assembly (5S rRNA) and rRNA processing (RNAse P and MRP). Thus, 
the down-regulation of RNA Polymerase III activity, resulting in ribosome 
biogenesis stress, should also be responsible for modulation of cell cycle 
progression.             
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Aim of the thesis 
 
The main purposes of this study are: 
 To characterize the effect of RNA Polymerase III depletion on ribosome    
   biogenesis by the analysis of nucleolar morphology, rRNA processing    
   status and ribosome subunit production 
 To verify the effect of RNA Polymerase III depletion  on cell cycle   
   progression  
 To define the molecular pathways linking RNA Polymerase III inhibition  
   to changes in the cell cycle progression 
The results that will be obtained might lead to a deeper understanding of the 
molecular pathway that controls the coordination between ribosome biogenesis 
and cell cycle, and might give useful information about the possibility to target 
RNA Polymerase III for cancer treatment.  
Before describing the results of the present thesis, a description of the molecular 
mechanisms controlling the cell cycle progression, the ribosome biogenesis and 
the established relationship between ribosome biogenesis and cell proliferation 
will be given. 
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Introduction 
 
2.1 Cell Cycle 
Tumorigenesis is the result of deregulation of cell cycle control elements which 
leads to aberrant cell proliferation. Cell cycle progression is regulated and 
monitored by a series of coordinated mechanism that ensure the passage through 
different cell cycle phases only after  transition of cell status monitoring 
checkpoints. The cell cycle divided in two main phases: Mitosis (phase M) and 
Interphase. While Interphase provides the passage through G1, S and G2 phases, 
the stage of Mitosis includes prophase, metaphase, anaphase and telophase, 
replication of DNA occurs in a specific part of the interphase called S phase  
(2. Norbury and Nurse, 1992). S phase is preceded by a gap called G1 during 
which the cell is preparing for DNA synthesis and followed by a gap called G2, 
when the cell prepares for mitosis. G1, S, G2 and M phases are the standard 
subdivisions of cell cycle. Cells in G1 can, before commitment to DNA 
replication, enter a resting state called G0. Cells in G0 phase account for the major 
part of the non-growing, non-proliferating cells in the human body. 
 
2.1.1 Cell cycle control by CDK/Cyclin system 
The passage from a cell cycle phase to another one is finely regulated by different 
cellular factors. The principal elements implicated in cell cycle regulation are 
Cyclin Dependent Kinases (CDK), a family of serine/threonine kinases that exert 
theirs activity during the different phases of cell cycle. Nine CDKs are identified 
in mammalian cells and five of these are involved in cell cycle regulation.  
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In particular G1 phase is characterized by the activity of CDK4, CDK6 and 
CDK2; S phase is linked to CDK2 activity, while G2 and M phase are CDK1 
dependent. The activity of CDK is regulated by the presence of their binding 
partners known as cyclins. While the protein levels of CDKs are constant during 
cell cycle progression, cyclins protein levels rise and fall in a selective manner 
during the different cell cycle phases and periodically activate  specific CDKs. 
(FIG. 2.1). The three D type cyclins (cyclin D1, cyclin D2, and cyclin D3) bind to 
CDK4 and CDK6, CDK-cyclin D complexes induce the entry in G1 phase  
(3. Sherr, 1994). Cyclin D is not expressed periodically, but is continuously 
synthesized in response to growth factor stimulation (4. Assoian and Zhu, 1997). 
Another G1 cyclin is cyclin E which associates with CDK2 to regulate 
progression from G1 into S phase (5. Ohtsubo et al. 1995) while cyclin A binds 
CDK2, promoting S phase progression. (6. Girard et al., 1991; 7. Walker and 
Maller 1991). At the end of G1 and at the early M, cyclin A binds CDK1 inducing 
the passage in Mitosis that will be characterized by binding of cyclin B with 
CDK1. (8. King et al., 1994; 9. Arellano and Moreno, 1997). To ensure specific 
degradation, each cyclins possesses peculiar protein sequence like Destruction 
box (Cyclin A and B) or PEST domain (Cyclin D and E) which are essential for 
efficient ubiquitin-mediated cyclin proteolysis at the end of each cell cycle phase. 
(10. Glotzer et al., 1991). However, regulation of cyclins levels is not the only cell 
strategy to control the intricate progression through cell cycle. In fact, CDK are 
also regulated by phosphorylation of Tyrosine and Threonine residues. For 
example CDK1, CDK4 and CDK2 full activation is detectable when are 
phosphorylated by CDK7/cyclin H complex, also called CAK. The 
phosphorylation CDKs induce protein conformational changes that lead to 
efficient cyclins binding. (11. Jeffrey et al. 1995). Wee1 and Myt1 kinases 
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phosphorylate CDK1 at tyrosine-15 or threonine-14, thereby inactivating the 
kinase. Dephosphorylation at these sites by the enzyme Cdc25 is necessary for 
activation of CDK1 and further progression through the cell cycle.  
(12. Lew and Kornbluth, 1996). In addition, proliferating cells utilize another kind 
of regulation that provides the activity of cell cycle inhibitory proteins inhibitors 
(CKI). In fact CDKs function can be also inhibited by specific CKIs. CKIs can be 
divided in two family: the INK4 and Cip/Kip family (13. Sherr and Roberts 
1995). The INK4 family includes p15 (INK4b), p16 (INK4a), p18 (INK4c), p19 
(INK4d), which specifically inactivate CDK4 and CDK6, involved in G1 
regulation. These CKIs form stable complexes with the CDK enzyme before 
cyclin binding, preventing association with cyclin D (14. Carnero and Hannon 
1998). The second group of CKIs, the Cip/Kip family, includes p21 (Waf1, Cip1), 
p27 (Cip2), p57 (Kip2). These inhibitors bind CDK/Cyclin complexes  
(15. Polyak et al., 1994). Cip/Kip family inhibit the CDK/Cyclin complexes 
necessary for G1 phase initiation and progression, and to a lesser extent, CDK1-
cyclin B complexes, involved in phase M regulation (16. Hengst and Reed, 1998). 
P21 also inhibits DNA synthesis by binding to and inhibiting the proliferating cell 
nuclear antigen (PCNA) (17. Pan et al. 1995). 
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FIG 2.1 
 
FIG 2.1:  Schematic representation of some of the mammalian CDKs involved in progression 
throughout the different phases of the cell cycle. 
 
 
 Different line of evidence have been shown that CKI can be regulated both by 
internal and external signals. An example is given by the fact that the expression 
of p21 is under transcriptional control of the p53 tumor suppressor gene,  
(18. Deiry et al., 1993) while the expression and activation of, respectively, p15 
and p27, increases in response to transforming growth factor b (TGF-b), 
contributing to growth arrest (19. Hannon and Beach 1994). Another level of cell 
cycle regulation is linked to the cellular localization of regulatory elements. 
Cyclin B contains a nuclear exclusion signal and is actively exported from the 
nucleus until the beginning of the prophase, while CDK inactivating kinases 
Wee1 and Myt1 are located, respectively, in the nucleus and Golgi complex  
and protect the cell from premature mitosis (20. Heald et al., 1993; 21. Liu et al., 
1997). Moreover, the intracellular trafficking of different proteins is regulated by 
14-3-3 complex. During interphase, the CDK activating kinase, Cdc25, is kept in 
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the cytoplasm through interaction with 14-3-3 proteins which are also able to 
sequester the CDK1-cyclin B complex following DNA damage (22. Yang et al., 
1999). Under this controlled regulation, CDKs can exert theirs kinase function on 
specific target substrates, to achieve the passages trough the different cell cycle 
phases.  During G1 phase CDK4/6 are active and are able to phosphorylate the 
product of retinoblastoma tumor suppressor gene (pRB). pRB is 
ipophosphorylated during early G1 phase, but once iperphosphorylated by CDKs, 
the tumor suppressor provides the release of E2F1 and DP-1, two of the most 
important transcription factors involved in cell cycle progression. In fact they 
positively regulate the transcription of genes whose products are required for S 
phase progression, including cyclin A, cyclin E and Cdc25. (23. Brehm et al. 
1998, 24. Kato et al. 1993). Afterwards, the activity of CDK2/Cyclin E ensures 
the maintenance of the iperphosphorylated form of pRB during the rest of cell 
cycle. In G1/S passage CDK2/Cyclin E phosphorylates its inhibitor p27 and lead 
to its proteasome-dependent degradation. (25. Montagnoli et al. 1999). CDK2-
cyclin E phosphorylates histone H1 and this activity may be important for 
chromosome condensation required during DNA replication. Histone H1 is also a 
substrate for CDK1-cyclin B. Cyclin A-dependent kinases regulate initiation of 
DNA replication by phosphorylation of DNA polymerase alpha primase. Other 
CDK substrates include CDK’s own regulators Wee1 and Cdc25, and cytoskeletal 
proteins such as nuclear lamins, microtubules and vimentin, which are required 
for correct mitosis (26. Heald and McKeon 1990; 27. Courvalin et al. 1992; 28. 
Hoffmann et al. 1993; 29. Blangy et al. 1995). 
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2.1.2 Cell Cycle checkpoints 
To ensure survival and generation of healthy progeny, eukaryotic cells respond to 
damaged, abnormally structured DNA or to alteration of protein synthesis 
machinery by a multifaceted response that coordinates cell cycle progression with 
DNA repair, chromatin remodeling, transcriptional and post-transcriptional 
programs, metabolic adjustment and finally cell death. 
The arrest or delay of cell cycle progression that provides time for DNA repair or 
for sufficient cellular component production needed for daughter cells generation 
is mediated by a network of signaling pathways identified as cell cycle 
checkpoints. These biochemical cascades include different type of sensor proteins 
that are able to monitor a series of cellular conditions like genome integrity, 
protein synthesis state or altered gene expression and help to generate signals that 
are transduced to downstream checkpoint effectors leading to cell cycle 
progression regulation. Each cell cycle phase is characterized by specific 
checkpoints pathways that operate in different way to ensure a coordinated control 
of cell cycle progression. (FIG.2). During G1 phase, cells with damaged DNA can 
activate the checkpoint transducing kinases ATM/ATR and ChK1/ChK2 which in 
turn target two critical effectors of G1 checkpoint, the tumor suppressor p53 and 
the Cdc25 phosphatase. Phosphorylation of Cdc25A by Chk1 and Chk2 induces 
its ubiquitination and proteasome-mediated degradation, preventing the 
dephosphorylation and activation of CDK2. The inhibition of CDK2/Cyclin E-
Cyclin A complex blocks the loading of Cdc45 on chromatin, interfering with α-
Polymerase recruitment and DNA replication initiation. (30. J. Falck et al., 2002). 
This checkpoint pathway operates independently of p53, it is quite transient and it 
is able to delay cell cycle progression only for several hours. The other 
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mechanism that mediates G1 checkpoint is p53 dependent and ensures a 
prolonged maintenance of G1 cell cycle arrest. p53 is phosphorylated by both 
Chk1/Chk2 and ATM/ATR. In addition Human Double Minute 2 
(HDM2/MDM2), the E3 ubiquitin ligase responsible for continuous p53 
proteasome-degradation during cell cycle progression, is also targeted and 
inhibited by ATM/ATR kinases. All these modification leads to p53 protein 
stabilization and to the subsequent transcription of its target genes such as the 
CDK inhibitor p21 (WAF1/Cip1). The accumulation of p21 leads to 
CDK2/Cyclin E complex inhibition, blocking pRB iper-phosphorylation, E2F1 
transcription and G1/S transition. (31. C.J. Sherr, J.M. Roberts 1999). The 
prolonged G1 cell cycle arrest can also lead to a permanent block in cell cycle 
progression and is related to the cell enter in G0 phase, phenomenon known as 
cellular senescence. Despite G1 checkpoints, the S phase checkpoint causes only 
transient and reversible delay in cell cycle progression, by slowing DNA 
replication or inhibition of new replicon formation.  
The pathway that link DNA damage to the core cell cycle machinery during S 
phase is the same described for G1/S checkpoint, providing the activation of 
ATM/ATR-ChK1/ChK2-Cdc25A-CDK2/CyclinE-Cdc45 cascade.  
The G2 checkpoint prevents cycling cells to start Mitosis when they experience 
DNA damage during G2, or if they proceed in G2 with some unrepaired damage 
or alteration inflicted during previous phases. Like G1 checkpoint, the G2 arrest 
or delay is a result of combination of rapid, reversible mechanism or prolonged, 
sustained response. The downstream target of G2/M checkpoint is represented by 
CDK1/Cyclin B complex. After DNA damage ATM/ATR and Chk1/Chk2 kinases 
phosphorylates and inhibit Cdc25C phosphatase, which is required for CDK1 
activation. Inhibition of CDK1 prevents the progression in M phase  
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(32. K.A. Nyberg et al. 2002). However, the long term arrest of G2 phase is driven 
again by p53 pathway. While G1 arrest is mediated by p21 mediated inhibition of 
CDK 2, CDK 1 activity is depleted by other p53 targets such as GADD45 or 
 14-3-3 proteins. (33. W.R. Taylor, G.R. Stark. 2001). 
Finally the ‘spindle checkpoint’ is direct to detection of improper alignment of the 
chromosomes on the mitotic spindle and stops the cell cycle in metaphase. 
If defects in microtubule attachment occurs during metaphase, Mitotic arrest 
deficient (Mad) and budding uninhibited by benomyl (Bub) proteins are activated 
and inhibit the Cdc20 subunit of the anaphase-promoting complex (APC), 
resulting in the prevention of anaphase transition (34. Fang et al. 1998). 
 
FIG 2.2: 
 
FIG 2: Mammalian Cell Cycle Checkpoints 
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2.2 The tumor suppressor p53 
 
The most common anti-apoptotic change that characterizes cancers is the 
inactivation of p53 tumor suppressor pathway. As discussed above p53 is the 
main regulator of G1/S or G2/M checkpoints, thus is essential for a controlled cell 
cycle progression. p53 function in cancer can be lost by different mechanism, 
including lesions that prevent p53 activation, mutation in TP53 gene or mutation 
in downstream effectors mediators of p53 function. Analysis of many tumors 
revealed that TP53 is mutated in about half of all type of cancers, resulting in loss 
of cell cycle control and apoptotic function. 
 
2.2.1 p53 protein structure 
The p53 tumor suppressor belongs to a small family of related proteins that 
includes two other members, p63 and p73. p53 is classified as transcription factor 
and is biologically active as a homotetramer comprising 393 amino acid residues 
for each homomonomer. It is characterized by a modular domain structure, 
consisting of folded DNA-binding and tetramerization domains, flanked by 
intrinsically disordered regions at both the amino terminal and carboxy-terminal 
domains. (FIG.2.3). The structure of the DNA-binding core domain (residues 94-
292) consists of a central immunoglobulin-like β-sandwich scaffold and additional 
structural elements that form the DNA-binding surface which include a loop-
sheet-helix motif and two large loops (L2 and L3). Human p53 core domain 
possesses low intrinsic thermodynamic stability and rapidly unfolds at body 
temperature with a half-life of 9 minutes (35. Bullock et al., 1997).  
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FIG.2.3 
      
 
 
FIG. 2.3: Schematic representation of p53 protein domains and structures. p53 contains an amino-
terminal transactivation domain (TAD), subdivided into the subdomains TAD1 and TAD2, 
followed by a proline-rich region (PRR). DNA-binding and tetramerization domains (OD) are 
connected through a flexible linker region. The regulatory domain at the extreme carboxyl 
terminus is intrinsically disordered (CTD). The vertical bars indicate the relative missense-
mutation frequency in human cancer for each residues. The structure of the DNA-binding domain 
(PDB code 1TSR) is shown as a ribbon representation and colored with a rainbow gradient from 
the amino terminus (blue) to the carboxyl terminus (red). Sites of cancer hotspot mutations and 
essential DNA contacts are shown as stick models. 
(From Andreas C. Joerger and Alan R. Fersht, 2010) 
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This low thermodynamic and kinetic stability may allow for rapid passages 
between folded and unfolded states, which could provide an additional level of 
regulation of functionally active cellular protein levels, besides the specific 
degradation pathways involving ubiquitination and subsequent proteasome 
mediated degradation The low stability of the core domain has profound 
implications with regard to the susceptibility of human p53 to deleterious 
mutations and cancer development and may also be directly linked with the 
structural plasticity required to facilitate binding to different partner proteins. p53 
can bind DNA only in a tetrameric form and crystallographic data have provided 
detailed insights into the structural basis of sequence specific DNA recognition by 
p53 tetramers. Two core domains bind to a half-site DNA, forming a symmetrical 
dimer with a relatively small, self-complementary core domain-core domain 
interface. The L3 loop binds to the DNA minor groove via Arg248, which makes 
either direct or water-mediated contacts with the DNA backbone.  The 
oligomerization state of p53 is regulated via its tetramerization domain (residues 
325–355 in human p53). However the individual subunits consist of a short β-
strand followed by α-helix. These two structural elements are connected by a 
sharp turn facilitated by a conserved glycine residue (Gly334). Four chains form a 
tetramer that can be described as a dimer of primary dimers. Additionally, 
increasing evidence suggest that the oligomerization equilibrium of p53 is 
modulated via an intricate network of accessory proteins, which can have either 
positive or negative regulatory effects. Most somatic p53 cancer mutations are 
located in the DNA-binding domain (Fig. 2.3) and these mutant proteins have, 
therefore, an intact tetramerization domain. Formation of mixed tetramers of 
impaired activity between wild-type and mutant p53 is thought to be the 
molecular basis of the so-called dominant–negative effect of mutant p53 in 
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heterozygous cells (36. Kern et al., 1992; 37. Dong et al., 2007). The amino-
terminal transactivation domain (TAD) is essential for p53 transcriptional activity. 
It connects target gene recognition with target gene expression by direct binding 
to transcriptional coactivators like p300/CBP and components of the basal 
transcription machinery (38. Thut et al. 1995; 39. Lill et al. 1997). The p300 is 
able to bind to the full TAD (TAD1/TAD2), but the TAD1 subdomain also binds 
strongly to the negative regulators MDM2 and MDMX that play a crucial role in 
controlling cellular p53 levels by promoting p53 degradation through the 
ubiquitin-dependent proteasome pathway (40. Marine et al., 2006). The p53 TAD 
is intrinsically disordered with two regions of nascent secondary structure. 
Intrinsic disorder is a characteristic of transactivation domains of transcription 
factors (41. Liu et al., 2006) and it is often associated with the presence of so-
called molecular recognition features, short sequence motifs that undergo 
disorder-to-order transition on binding to partner proteins (42., Mohan et al. 
2006), allowing promiscuous binding of different targets at the same site by 
providing conformational variability and adaptability. Changes in the affinity of 
p53 for competing binding partners in the cell cycle by post-translational 
modification of TAD, allows modulation of p53 activity in response to cellular 
stresses. 
 
2.2.2 p53 target genes 
Several responses can be induced by p53, including cell-cycle arrest, senescence, 
differentiation and apoptosis, with the option chosen being dependent on many 
factors that are both intrinsic and extrinsic to the cell. However, a strong induction 
of p53 may leads to an irreversible inhibition of cell growth, most decisively by 
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activating apoptosis, while the modulation of p53 levels leads to a controlled 
regulation of cell cycle progression. p53 target can be divided in different group 
of proteins that act on various cell stress response mechanisms such as G1 or G2 
cell cycle arrest, DNA repair, inhibition of angiogenesis, inhibition of metastasis 
and apoptosis. The most know target, involved in G1 cell cycle arrest, is 
represented by P21 (Waf1/Cip1) a CKI of the Cip/Kip family responsible for the 
inhibition of CDK2/Cyclin E activity. In addition to the inhibition of 
CDK2/Cyclin E complexes, p53 regulates a variety of genes that also contribute to 
G1 arrest. It is involved in regulation of the cyclin E activity by the induction of 
hCDC4b (43. Kimura T. et al. 2003). It was shown that hCDC4b, an F box protein 
and component of the SCF ubiquitin ligase complex, targets cyclin E for 
ubiquitin-mediated degradation. p21 can also participate in G2 arrest, is able to 
associates with CDK2/Cyclin B complex and inhibits the activating 
phosphorylation of CDK2 by CAK (44. Smits V. A., 2000). In addition, the 
Growth Arrest and DNA Damage inducible protein (GADD45), another p53 
target gene, binds CDK2, preventing CDK2/Cyclin B complex formation and 
subsequently inhibition of kinase activity (45. Zhan Q. et al., 1999). From P53 
target gene involved in DNA repair there are again GADD45 which take part in 
Topoisomerase mediated relaxing of chromatin (46. Maeda T. et al., 2002). Other 
targets of P53 are represented by xeroderma pigmentosum group E and C gene 
(XPE, XPC). The last two are responsible for nucleotide excision repair (NER). 
(47. Hwang B. J. et al., 1999; 48. Adimoolam S. and Ford J. M., 2002). p53 also 
induce the transcription of genes that are implicated in inhibition of angiogenesis. 
TSP-1, an extracellular matrix glycoprotein is responsible for angiogenesis 
inhibition and is activated by p53. (49. Dameron K. M., 1994). Furthermore p53 
can also repress VEGF expression, an important enhancer of endothelial cell 
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growth. (50. Zhang L. et al., 2000). p53 exerts also the capacity to inhibit 
metastatic behavior by inducing the transcription of genes involved in  control of 
extracellular matrix (ECM) degradation. p53 induces the expression of at least 
two Serpins, Plasminogen Activator Inhibitor-1 (PAI-1) and Maspin (51. Kunz C. 
et al., 1995) . PAI-1 functions to inhibit urokinase-type plasminogen activator  
(u-PA) and u-PA initiates a cascade of cleavages that ultimately result in the 
activation of plasmin. Plasmin degrades a wide variety of ECM proteins such as 
fibrin, fibronectin and laminin. By inducing PAI-1, the metastatic potential of 
tumor cells is decreased. On the other hand, Maspin has been shown to interact 
with collagen type I and III, increasing cell adhesion to the ECM. (52. Blacque O. 
E., 2002). In addition, many p53 pro-apoptotic target genes have been identified 
in the last years, leading to evidence that the tumor suppressor can regulate both 
the intrinsic and extrinsic apoptotic pathways. In fact the transcription factor can 
induce the expression of two cell surface death receptors, Fas/CD95 and 
KILLER/DR5, and of the ligand of Fas, named FasL, which are involved in 
extrinsic apoptosis induction. Activation of the initiator caspase-8, another p53 
target gene, eventually leads to stimulation of effector caspases and mediation of 
extrinsic apoptosis. (53. Fukazawa T. et al. 1999). It was also shown that p53 is 
able to induce the expression of tumor necrosis receptor associated factor 4 
(TRAF4) which induces apoptosis and inhibits colony formation (54. Sax J. K. 
2003). As well as for the extrinsic apoptotic pathway, p53 is able to upregulate the 
expression of proteins regulating the intrinsic apoptotic pathway. Many of these 
proteins localize to the mitochondria and regulate the release of Cytochrome C. 
These mitochondrial localizing proteins include both Bcl-2 family proteins and 
non-Bcl-2 family members. Two non-Bcl-2 family members regulated by p53 
include p53AIP1 and mtCLIC/CLIC4 (55. Fernandez-Salas E. et al., 2002), while 
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the Bcl-2 family proteins include BAX, NOXA, p53 upregulated modulator of 
apoptosis (PUMA), BID, BCL-2 and BCL-X (56. Oda E. et al., 2000;  57. Sugars 
K. L., 2001). With this set of target genes the tumor suppressor p53 ensure a 
strong response to different types of cellular stresses regulating pathways involved 
in cell cycle control and cell viability.  
 
2.2.3 MDM2 mediated p53 regulation. 
The regulation of p53 activity mainly depends on Human Double Minute 2 
(HDM2/MDM2). MDM2 was discovered in a locus amplified on double minute 
chromosome in a tumorigenic mouse cell line known as 3T3-DM  
(58. Fakharzadeh S.S. et al., 1991). The main function of MDM2 is to negatively 
regulate the levels and functions of tumor suppressor p53 protein. High MDM2 
levels decreases p53 activity, leading to increased cancer risk or to accelerated 
tumor development. Different sets of human tumors are characterized by MDM2 
amplification or increased transcriptional level. MDM2 is a RING finger E3 
ligase, characterized by an N-terminal domain containing p53 binding site, a 
central region with nuclear localization and export sequences, an acidic domain, a 
zinc finger domain, binding site for TBP, p300 and ARF; and a C-terminal region 
with RING finger domain (59. Thut C.J., 1997; 60. Grossman S.R., 1998; 61. 
Midgley C.A., 2000). RING finger domain can bind to an E2 ubiquitin-
conjugating enzyme, leading to ubiquitin binding of target proteins. p53 represent 
the principal target of MDM2 which is able to monoubiquitinate or 
polyubiquitinate the tumor suppressor. Interaction of MDM2 with p53 mediates 
the translocation of the tumor suppressor in the cytoplasm (62. Roth J. 1998), 
sequestering it from nuclear functions. Thereafter cytoplasmic proteasomes 
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recognize polyubiquitination signal and target p53 for degradation. On the other 
hand the binding of MDM2 to the N-terminal domain of p53 inhibits its 
interaction with transcription machinery and deplete also its transcription 
functions. (63. Momand J. et al. 1992). 
Another member of MDM2 family can regulate p53 function. MDM4, also called 
MDMX contains an N-terminal p53 binding site, a central acidic domain and a C-
terminal RING finger domain. MDM4 is unable to induce p53 degradation but 
can bind it and inhibit its transcription activity (64. Toledo F., Wahl G.M. 2007). 
The main regulation of MDM2 depends on an autoregolatory feedback loop 
system. The oncogene is in fact a transcriptional target of p53 (65. Barak Y. 
1993). However, MDM2 activity is also regulated by different extracellular and 
intracellular mechanism, leading to a smart modulation of p53 function. First of 
all MDM2 is regulated after DNA damage. In response to ionizing radiation, 
ATM phosphorylate p53, reducing the affinity for MDM2 binding and its 
consequent degradation. ATM is also responsible for MDM2 phosphorylation 
which affects its ability to export p53 in the cytoplasm, where proteasomes 
mediated degradation take place (66. Maya R. et al., 2001). Another ATM activity 
provides the stimulation of HAUSP, a specific p53 and MDM2 de-ubiquitinase 
and cause stabilization of the tumor suppressor (67. Meulmeester E. et al., 2005). 
UV radiation acts by another pathway and stimulate ATR mediated 
phosphorylation of MDM2 interfering again with p53 shuttling from nucleus  
(68. Shinozaki T et al., 2003). MDM2 undergoes also a regulation mediated by 
oncogenic stress. Aberrant activation of different oncogenes like E2F-1, β-
Catenin, Myc, Ras or Nucleophosmin increase the protein levels of p14/p19 ARF 
which is responsible for MDM2 inhibition (69. Zhu J.W. 1999; 70. Damalas A. et 
al., 2001; 71. Korgaonkar C. et al., 2005; 72. Moulin S. et al., 2008 ).  
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High level of ARF proteins correlates with MDM2 binding and segregation of 
MDM2 from P53. Furthermore the interaction between ARF and MDM2 inhibit 
E3 ubiquitinase action toward p53, which increase again p53 protein level. (73. 
Weber J.D. et al., 1999). Progressive transition through cell cycle is another 
cellular mechanism linked to MDM2 regulation and p53 control.  
It was shown that MDM2 contain a Cyclin recognition motif. CDK1/Cyclin A and 
CDK2/Cyclin A complexes bind and phosphorylate the oncogene protein product. 
The phosphorylated form of MDM2 exerts a reduced interaction with p53 and on 
the other hand an increased affinity for ARF binding. These events clearly result 
in P53 stabilization (74. Zhang T. and Prives C., 2001). Finally MDM2-p53 
feedback loop is also regulated by another important mechanism that link control 
of ribosome biogenesis to cell cycle regulation. Ribosome biogenesis alterations 
at different level bring to cell cycle arrest induced by MDM2-p53 pathway. The 
mediators of this stress response are the same ribosomal proteins involved in 
ribosome construction and represent the regulatory elements that are able to bind 
and inhibit MDM2. The depletion of MDM2 functions, clearly affects 
ubiquitination of p53, leading to its stabilization, cell cycle arrest and eventually 
apoptosis. This fascinating stress response will be discussed in detail in the next 
chapters. 
 
2.3 Ribosome Biogenesis 
 
As mentioned above, protein synthesis is necessary for cell growth and cell 
proliferation. The cellular machinery involved in protein production is represented 
by Ribosomes. The process that leads to the building of the mature ribosome 
subunits, known as 40S and 60S, is defined as Ribosome Biogenesis and must be 
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continuously controlled in proliferating cells to ensure the correct coordination of 
protein synthesis with the cell cycle progression. The site of ribosome production 
is represented by nucleolus, a non-membranous structure located in the nucleus of 
eukaryotic cells.  
 
 
2.3.1 The nucleolus 
Nucleolus is the site of ribosome biogenesis. It has been shown that cancer cells 
are characterized by elevated rates of ribosome biogenesis and protein synthesis 
and show irregular shaped and hypertrophic nucleoli, compared with those of 
normal growing cells. Furthermore, there is evidence that changes in nucleolar 
morphology and function may depend both on rate and status of ribosome 
biogenesis and on proliferative activity of cycling cells (75. Montanaro L. et al. 
2008). The nucleolus can be easily detected by contrast-phase light microscopy in 
living cells, as the consequence of the higher concentration of RNA and proteins 
in the nucleolus than in the nucleoplasm. At the electron microscopy level, 
mammalian cell nucleoli constantly exhibit three major components: fibrillar 
centers (FCs), which appears as roundish structures of varying size, with a very 
low electron opacity; the dense fibrillar component (DFC), which frequently 
constitutes a rim intimately associated with the fibrillar centers, composed of 
densely packed fibrils; and the granular component (GC), composed of granules 
that surround the fibrillar components (FIG. 2.4). (75. Montanaro L. et al. 2008).  
Ribosomal genes under active transcription are located at the boundary between 
FC and DFC. The DFC is the site where early steps of rRNA processing take 
place while the CG is the site of late rRNA processing and ribosome subunit 
building. (76. Raska I. et al., 2006). Therefore, the fibrillar centers plus the 
25 
 
associated dense fibrillar components can be considered to represent the 
structural-functional units of the nucleolus where rRNA molecules are produced. 
A large set of proteins involved both in rRNA genes transcription and in rRNA 
processing such as Nucleophosmin, Nucleolin, UBF and others component, which 
are located both  in the FCs and the DFC, can be selectively visualized by a silver 
stain method used for the analysis of Nucleolar Organizer Region (NOR) on 
metaphase chromosomes (AgNOR staining). The silver-stained proteins are 
defined as AgNOR proteins and the quantification of the AgNOR stained 
structures represents a useful method to evaluate the rRNA transcriptional activity 
at light microscope level. (77. Derenzini M.et al. 1990).  
 
FIG. 2.4: 
                             
FIG. 2.4:  Nucleolus of established cell lines from human fallopian tube cancer. (TG cells) 
The sample was stained with uranium and lead and visualized by Electron Microscopy. 
Asterisks indicate Fibrillar Centers (FC), while “f” surrounds the Dense fibrillar 
component (DFC). Granular Component (GC) is indicated by “g”. 
(From : Nucleolus, Ribosomes and Cancer. Montanaro L., Trerè D.and Massimo Derenzini. 
The American Journal of pathology, 173, 2. 2008). 
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2.3.2 Ribosomal RNA maturation and ribosome subunits 
production. 
The biosynthesis of ribosomes is a complex multistep process which requires the 
coordinated activity of all the three DNA dependent RNA Polymerases. In 
particular: RNA Polymerase I (Pol I) is responsible for transcription of a large 
rRNA precursor known as 47S, RNA Polymerase II (Pol II) transcribes the 
messenger RNA (mRNA) for ribosomal protein synthesis, the accessory factors 
and the small nuclear RNA (snoRNA), involved in rRNA modification and 
processing, and RNA Polymerase III (Pol III) provides the transcription of rRNA 
5S and others non-coding RNAs (ncRNA) needed for ribosome construction. In 
eukaryotes the mature ribosome is constituted by two subunits. The small 40S 
subunit (SSU) contain a single 18S rRNA and at least 30 ribosomal proteins, 
while the large 60S subunit (LSU) consist of three rRNA (5S, 5.8S and 28S 
rRNA) as well as about 50 ribosomal proteins. (78. Woolford and Warner, 1991). 
(FIG.2.5) 
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FIG. 2.5 
 
FIG. 2.5 Schematic representation of the main ribosome biogenesis steps. 
(From Ribosome Biogenesis: From Structure to Dynamics, 
Barbara Cisterna and Marco Biggiogera International Review 
of Cell and Molecular Biology, Volume 284. 2010). 
 
 
                                       
The precursor rRNA 47S contains the sequences of mature rRNAs which are 
separated by two internal transcribed region defined as ITS1 and ITS2. The 
external side of each spacer is occupied by external transcribed regions known as 
5’ ETS and 3’ ETS. Generation of mature ribosome subunit requires the 
coordinated action of a series of factors needed for the structural composition of 
mature ribosomes such as ribosomal proteins, or accessory factors like exoRNases 
or esoRNases and snoRNA, which are responsible for covalent modification of 
rRNA precursor in specific nucleotide sequences. SnoRNAs are short (60-300 
nucleotides long), stable RNAs that localize within the nucleolus (79. Watkins 
and Bohnsack 2011). SnoRNAs act mainly as anti-sense guides in RNA 
modification and are carried by small nucleolar ribonucleoproteins (snoRNPs), 
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like Fibrillarin, a methyltransferase (C/D box snoRNAs) or Dyskerin, a 
pseudouridine synthase (H/ACA box snoRNA), to the site of RNA modification. 
Global rRNA pseudouridylation was recently shown to be important for the 
binding of ligands to the ribosome, as well as for translation fidelity and the  
Internal Ribosome Entry Site (IRES) dependent translation (80.  K. Jack., 2011) 
and global methylation is now also known to be important for IRES-dependent 
translation (81. Basu A. et al., 2011). In addition, a set of snoRNAs are involved 
in pre-rRNA processing (U3, U8, U17, U22) and it is understood that this also 
requires base-pairing with the pre-rRNAs. The whole set of factors needed for 
ribosome biogenesis is recruited inside the nucleolus where associates with 
nascent rRNA precursor and leads to the formation of a 90S pre-ribosomal 
particle, a macromolecular structure in dynamic evolution which reaches its 
mature and functional form during its traffic from the nucleolus to cytoplasm. The 
90S pre-ribosomal particle must be split by a series of progressive modifications 
and cleavages, in pre 60S and pre 40S subunits, which follow two separate 
maturation route (FIG.2.6).  
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                                                          FIG.2.6 
           
FIG. 2.6: Pre-rRNA processing in Humans 
(From: Mapping the cleavage sites on mammalian pre-rRNAs: Where do we stand? 
Mullineux S. T., Lafontaine D. (Biochimie 94, 1521-1532. 2012) 
 
 
The processing pathway starts with cleavage of the 47S at both ends of the 
molecule, at sites 01 and 02, generating the 45S precursor which is primarily 
processed by two alternative pathways. In pathway 1 processing is initiated in the 
5’-ETS by concomitant cleavage at sites A0 and 1. This step generates the 41S 
pre-rRNA which is cleaved at site 2 into 21S and 32S precursor rRNAs species. 
The cleavage of 41S pre-RNA leads to the formation of SSU and LSU pre-
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ribosomal particles. The 21S is successively trimmed to sites C and E giving rise 
to 18S-E pre-rRNA. The last one is then exported to the cytoplasm where it is 
cleaved at site 3 to generate the 18S rRNA. The maturation of the LSU require the 
processing of the 32S pre-rRNA which is cleaved at site 3’ in ITS2, generating the 
12S pre-rRNA and the mature 28S rRNA. The 12S is cut at site 4a into 7S and 
then at site 4’ to generate the 5.8S rRNA. Conversely, in pathway 2, where 
processing starts in ITS1 at site 2, the 30S is directly matured into 21S by 
simultaneous processing at sites A0 and 1, or through the formation of a 26S pre-
rRNA intermediate. (82. Mullineux S.T. and Lafontaine D., 2012). Furthermore, 
differently from the maturation of the others rRNAs, the 5S rRNA, transcribed by 
RNA Polymerase III, after the processing of only few nucleotides at 3’end, shuttle 
in the cytoplasm and interact with Rrs1 and Rrs2, which are implicated in the 
recruitment the rRNA 5S, within two ribosomal proteins of the large subunit 
(RPL11 and RPL5) in the LSU pre ribosomal particle. (83. Zhang et al., 2007). At 
the end of ribosome biogenesis mature ribosome subunits 40S and 60S are ready 
to associates with messenger RNA (mRNA) in the cytoplasm leading to the 
assembly of the mature 80S, which will start the protein synthesis.   
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2.4 Modulation of cell cycle regulators and control of 
ribosome biogenesis 
Depending on their function as positive or negative effectors of cell cycle 
progression, different cell cycle regulators can influence ribosome biogenesis 
status by stimulation or inhibition of RNA Polymerases activity. Extracellular 
signals, such as mitogens, upregulate the RNA Polymerases activity and lead to 
increase of ribosome biogenesis. Extracellular signal-regulated kinases (ERKs) 
are activated in response to different mitogens through a signal transducing 
cascade that involves Ras, Raf and ERK kinase MEK.  
It has been shown that ERK phosphorylates and activates the transcription 
intermediary factor 1 A (TIF1A), a transcription factor required for specific 
promoter recruitment of Pol I. (84.. Zhao, J. et al. 2003). ERK is also able to 
interact with upstream binding factor I (UBF) and stimulate its function of Pol I 
recruitment on rDNA.(85. Stefanovsky, V. Y. et al. 2001). ERK mediated 
phosphorylation also increases the efficiency of specific general transcription 
factor 3 B (TF3B), which is necessary for Pol III  mediated transcription  
(86. Felton-Edkins, Z. A., 2003).  The stimulation of Pol I and Pol III activity by 
ERK ensure that 47S rRNA, 5S rRNA and tRNAs are synthetized in a coordinated 
manner in response to mitogenic stimuli. Another crucial factor that finely tunes ribosome 
biogenesis and cell cycle progression is the oncogene Myc. Known as a target of ERK 
mediated signals, Myc can regulates the transcription of a  huge set  of genes, 
including those encoding ribosomal proteins, factors involved in ribosome 
production and translation factors. In addition Myc stimulates directly the activity 
of PolI by inducing the transcription of UBF or by the binding with promoter 
selective factor I (SL1), responsible for PolI recruitment on its target promoters. 
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(87. Poortinga, G. et al. 2004;  88. Grandori C. et al. 2005).  On the other hand, 
Myc can also increase Pol III activity via TF3B interaction. (89. Gomez-Roman, 
2003).  Deregulation of Myc expression is a common feature of a series of tumors 
like Burkitt lymphomas, Neuroblastomas and Colon Carcinomas. It is clear that 
such deregulation can affect the transcription of all the three RNA Polymerases 
and stimulate ribosome biogenesis rates. Apart from Myc, another key regulator 
of protein synthesis and cell growth is mammalian target of rapamycin (mTOR). 
(90. Fingar and Bleins, 2004). mTOR is known as a positive regulator of protein 
synthesis, increasing ribosome production and translational initiation. mTOR 
phosphorylates UBF in its C-terminal domain promoting its binding with SL1 and 
directing PolI on its target genes promoters. (91. Hannan, K. M. et al., 2003).  
Pol III activity is also regulated by mTOR which can bind TF3B and promotes 
recruitment of the enzyme on target genes. In parallel, mTOR inhibits Maf 1, a 
repressor of 5S rRNA and tRNA transcription. (92. Kantidakis T. et al. 2010). 
mTOR activity is upregulated in human cancers, due to changes in upstream 
control elements that influence also cell cycle progression such as Ras. These 
events correlate again with Ribosome biogenesis and protein synthesis 
stimulation. On the other hand, ribosome biogenesis is negatively controlled by 
different tumor suppressors which are also involved in the negative control of cell 
cycle progression. The tumor suppressor pRB is one of the most important factors 
involved in G1/S passage during cell cycle progression. It represses E2F1 activity, 
which stimulates the expression of proteins necessary for the S-phase entry. In 
parallel, pRB controls the rate of ribosome biogenesis by hindering the RNA 
Polymerases activity. UBF and TF3B can be targeted and sequestered by pRB to 
achieve the inhibition of Pol I or Pol III respectively. (93. Cavanaugh, A. H. et al., 
1995). Interestingly, when the demand for rRNA transcription is decreased, pRB 
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accumulates in nucleolus, while mitogenic stimulation leads to dissociation of 
pRB with UBF and TF3B, leading to a raise of rRNA and tRNA production.  
(94. Scott J. et al. 2000 ; 95. Hannan, K. M. et al. 2001). Modulation of RNA 
polymerases transcription can occur also in response to the activity of factors 
involved in cell cycle checkpoint control. The tumor suppressor p53, which is 
responsible for cell cycle arrest in G1/S or G2/M,  binds and sequestrates both 
SL1 and TFIIIB. (96.  Zhai W, Comai L. 2000; 97. Crighton, D. et al. 2003).  
Again the sequestration of transcription factors leads to a reduced production of 
rRNA and tRNAs. Moreover, upstream regulators of p53 may affect the Pol I and 
Pol III transcription. Oncogenic stress induced by Myc overexpression brings to 
the alternative transcription of INK4a/ARF locus, leading to the production of 
ARF. It is well known that ARF can bind and inhibit MDM2, thus inducing p53 
stabilization. On the other hand ARF is involved also in direct regulation of 
ribosome biogenesis. It has been demonstrated that ARF is able to block the 47S 
processing by the binding of Nucleophosmin (B23). ARF binding promotes the 
ubiquitination and subsequent degradation of B23, and cause the arrest of rRNA 
maturation. This pathway provides a more efficient checkpoint for coupling p53 
dependent inhibition of cell cycle progression with ribosome production. In 
parallel, the tumor suppressor p53 represents the main player of the stress 
response induced by alterations of ribosome biogenesis which also have a strong 
effect on cell cycle progression regulation. Indeed not only cell cycle regulators 
affect the activity of RNA Polymerases, but also ribosome biogenesis changes can 
modulate the function of  key factors involved in the regulation of transition 
through the different cell cycle phases.    
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2.5 Ribosome biogenesis alterations effects on nucleolar 
Morphology and cell cycle progression 
 
Ribosome biogenesis control is crucial for cell cycle progression, loss of this 
control result in altered cell cycle and deregulated cell growth (98. Ruggero and 
Pandolfi. 2003). Ribosome biogenesis alterations can involve the three major 
components necessary for ribosome production: rRNA, ribosomal proteins and 
ribosome processing factors. Available evidence indicates that the mechanism of 
p53 stabilization after ribosome biogenesis perturbation is mainly the result of the 
release from the nucleolus of several ribosomal proteins that bind to MDM2 and 
relieve its inhibitory activity toward p53 (99. Y. Zhang and H. 2009). (FIG 2.7).  
In the past years it has been shown that the inhibition of rRNA transcription, 
triggered by drugs such as actinomycin D (100. Y. Zhang et al., 2003), 5-
fluorouracil (101. Sun and Dai, 2007), mycophenolic acid (102. Sun and  Dai 
2008) or by TIF-IA depletion expression, lead to p53 stabilization. (103. X. Yuan 
et al., 2005) Similarly, alterations of rRNA processing pathway, due to an 
expression of a dominant negative form of Bop1, trigger again the activation of 
p53 pathway (104. Pestov et al., 2001). It has been postulated that, in order to 
stabilize p53, all cell stresses should induce a nucleolar disruption which can 
result in the release of the nucleolar proteins from the nucleolus to the 
nucleoplasm (105. Rubbi C.P., Milner j., 2003). Accordingly, the stabilization of 
p53 induced by the inhibition of rRNA transcription or inhibition of rRNA 
processing, was also thought to be caused by the release of RPs from the disrupted 
nucleolus. However, recent studies demonstrated that the nucleolar disruption was 
not a necessary condition for p53 stabilization after ribosome biogenesis 
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alterations. In fact, the down-regulation of rRNA synthesis induced by POLR1A 
silencing (106. Donati et al. 2011) or depletion of certain RPs, such as RPS6  
(107. Fumagalli et al., 2009), caused p53 stabilization without inducing changes 
in the nucleolar structure organization. Recently, it was shown that after selective 
down-regulation of rRNA synthesis, RPs which were no more required for 
ribosome biogenesis, bind to MDM2 in larger amounts, thus increasing p53 
stabilization. According to this model, the level of p53 stabilization appears to be 
the consequence of the availability of free ribosomal proteins not used for 
ribosome-subunit production. Therefore, it was not surprising that after 
stimulation of rRNA transcription, the ribosomal protein quantity that binds and 
inactivates MDM2 was reduced, thus resulting in a greater degradation of p53. In 
fact the up-regulation of rRNA synthesis in cancer cells induced by treatment with 
insulin or the insulin-like growth factor (IGF1) led to a decreased expression of 
p53. (106. Donati et al. 2011). This decrease is a consequence of the increased 
MDM2 mediated p53 proteasomal degradation due to the reduced availability of 
ribosomal proteins for MDM2 binding which were, in fact, used in a higher 
number for ribosome building. Among the pool of ribosomal proteins, RPL11 and 
RPL5 seem to exert a pivotal role in MDM2 inhibition. It was demonstrated that 
specific depletion of these ribosomal proteins mitigates p53 stabilization after 
induced ribosome biogenesis alterations. (108. Fumagalli S. et al. 2012). In 
addition recent studies have shown that RPL11 and RPL5 can bind MDM2 in 
cooperation with the 5S rRNA, which take part in 60S production with the large 
ribosomal proteins. (109. Horn H.F. and Vousden K.H. 2008).   
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FIG. 2.7: 
 
 
 
 
 
 
      
 
 
 
 
FIG. 2.7:  Schematic representation of ribosome biogenesis alteration effects on p53 
pathway activation. (From: Deisenroth C., Zhang Y. 2010) 
 
In summary, in cancers cells the upregulated ribosome biogenesis lead to an 
increased demand of ribosomal proteins for rRNA binding. Under these 
conditions, MDM2 ubiquitin ligase activity is not efficiently inhibited and p53 
protein levels may be reduced, leading to a downregulation of the cellular tumor 
suppression potential. Conversely, ribosome biogenesis alterations correlate with 
a reduced requirement of ribosomal protein for ribosome construction which in 
turn are more available for MDM2 binding. In this way, after ribosome biogenesis 
alterations, cycling cells can activate the p53 pathway to ensure cell cycle arrest or 
alternatively to start apoptotic program (1. Montanaro L. 2012).  
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2.6 RNA Polymerase III and Non-coding RNAs 
Eukaryotic cells utilize three distinct DNA Dependent RNA Polymerases each 
specialized in the transcription of specific classes of genes. Pol III synthesizes a 
set of small, non-coding RNAs (ncRNA) involved in regulation of essential 
cellular processes such as protein synthesis, ribosome production and rRNA 
processing. These ncRNAs include all tRNAs, 5S rRNA, splicing U6 RNA, signal 
recognition particle 7SL RNA, RNA components of RNase P and RNase MRP. 
(110. G.Dieci et al. 2007).  
 
2.6.1 Enzyme Structure 
RNA Polymerases share different subunits that are defined A, B or C by their 
affiliation to RNA Polymerase I, II or III. Human RNA Polymerase III is the 
largest and most complex among the three RNA polymerases and consists of 17 
different subunits with an overall mass of 700 KDa. 
The horse-shoe shaped core contains the two largest PolIII specific subunits C160 
(POLR3A) and C128 (POLR3B) encoded by polR3A and polR3B genes forming 
the active center and the nucleic acid binding cleft. C160 and C128 are 
responsible for the catalytic activity of the enzyme. As shown by different studies, 
depletion of C160 (POLR3A) with neutralizing antibodies, inhibits in vitro RNA 
Polymerase III transcription and mutations in polR3B gene are closely associated 
with hypomyelinating leukodystrophy-7 (111. G. Bernard et al. 2011). Other core 
components are two assembly subunits shared with Pol I (AC40 and AC19 
codified by polRC and polR1D genes), five peripheral subunits shared with Pol I 
and II (ABC27, ABC23, ABC14.5, ABC10β and ABC10α), and C11, a subunit 
that participates in RNA cleavage during backtracking. Attached to the core a 
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subcomplex, that contains subunits C17 and C25, forms an elongated stalk that 
provides a platform for initiation factors and is also involved in the interaction 
with newly synthesized ncRNAs (112. A.J. Jasiak et al. 2006). The stalk 
completes the group of 12 subunits that have counterparts in all three eukaryotic 
RNA polymerases. In addition, Pol III contains five specific subunits (C31, C34, 
C37, C53 and C82) organized in two distinct subcomplexes. One subcomplex 
corresponds to the C37/C53 heterodimer, which is the counterpart of Pol I 
subunits A49/A34.5 and is distantly related to Pol II initiation factor TFIIF. The 
C37/C53 heterodimer interacts with DNA inside the DNA-binding cleft and is 
involved in transcription initiation, elongation, termination and reinitiation. The 
other subcomplex corresponds to the C31/C82/C34 heterotrimer and is involved 
only in transcription initiation (113. R. Carter 2010). A structural organization of 
RNA Polymerase III enzyme is represented in FIG. 2.8 
 
FIG.2.8 
 
FIG. 2.8: Structural organization of the Pol III-specific subcomplexes. 
(From: Analyzing RNA polymerase III by electron cryomicroscopy 
Carlos Fernández-Tornero et al. RNA Biology 8:5, 760-765. 2011) 
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2.6.2 RNA Polymerase III products 
RNA Polymerase III transcribes a range of ncRNAs mainly derived from different 
promoters. Three types of promoter have been described as PolIII target. (FIG.2.9) 
FIG.2.9: 
     
FIG.2.9: Representation of the three class of RNA Polymerase III targeted promoters. 
 
Most Pol III target genes such as tRNA genes, are transcribed under the control of 
the first class of promoters. Class one promoters are characterized by nucleotides 
sequence blocks defined as A and B boxes in the transcribed region. The A and B 
boxes are recognized by general transcription factor (TF3C). TF3C recruits TF3B, 
which is composed of BDP1, BRF1 subunit and of the tata binding protein, 
known as TBP. The second type internal promoters are characteristic of 5S rRNA 
gene, which needs the specific binding of an additional TF3A to a C site, 
compared to the first type. The last class of promoters is characteristic of U6 
snoRNA genes. These promoters contain a TATA box, which is bound by TBP, 
and proximal sequence elements (PSEs), which is bound by small nuclear RNA 
activating protein complex (SNAPc) factor. (114. Orioli et al. 2011).  
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The major elements produced by the first class of promoters are tRNAs. tRNAs 
transport aminoacids into ribosomes and decipher triplets of nucleotides at each 
codon of mRNAs. High levels of tRNAs are also connected with tumorigenesis. It 
has been shown that tRNAs are overproduced in human ovarian cancers and 
overexpression of initiator tRNAi
met
 is oncogenic. (115. Winter et al. 2000; 116. 
Marshall et al. 2008). In addition a recent research suggests that tRNAs can also 
inhibit caspase activation by attenuation of cytochrome- c induced apoptosis (117. 
Mei et al. 2010). Another ncRNA transcribed by Pol III is 7SK RNA, a small 
nuclear RNA (snoRNA) of about 330 nucleotides. 7SK RNA binds to 
LARP7/PIP7S to form a small nuclear ribonucleoprotein (snRNP). 7SK snRNP, 
within HEXIM proteins, binds transcription elongation factor b (P-TEFb). P-
TEFb is required for phosphorylation of the C- terminal domain of Pol II, which 
lead to the transition of the enzyme from transcriptional initiation to elongation. 
HEXIM-7SKsnRNP-P-TEFb complex seems to be responsible for inhibition of 
the activity of P-TEFb and lead to negative modulation of Pol II mediated 
transcription. (118. Nguyen V.T. et al. 2001). Pol III also provides the 
transcription of MRP RNA, the RNA component of the mitochondrial RNA 
processing complex (RNase MRP). The RNase MRP is an essential eukaryotic 
ribonucleoprotein endoribonuclease involved in different molecular processes. 
The central region of MRP RNA is required for RNase MRP transport in 
mitochondria, where it cleaves RNA transcript to generate primers for 
mitochondrial DNA replication. However the snRNP exerts also nucleolar 
functions. It has been demonstrated in Saccharomyces Cerevisiae that RNase 
MRP complex possess the ability to process the rRNA precursors at the A3 site to 
form 5.8S rRNA. (119. Mattijssen S. et al., 2010). This study clearly demonstrates 
how MRP RNA function is important for a correct progression of ribosome 
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biogenesis. Since RNase MRP is highly conserved, similar function may exist 
also in higher eukaryotic organism, where genetic alterations of MRP RNA are 
coupled with disease development. Indeed, mutations in human MRP RNA gene 
are responsible for the development of an inherited pleiotropic syndrome, known 
as cartilage-hair hypoplasia. (120. Ridanpa M. et al. 2001). Moreover 7SL RNA is 
known as PolIII product and is a component of the signal recognition particle 
(SRP). 7SL RNA occupies the center of the SRP complex and offers binding sites 
for six proteins (SRP9, SRP14, SRP19, SRP54, SRP68 and SRP72).   
In particular SRP address the nascent polypeptide chains and membrane proteins 
to the endoplasmatic reticulum. (121. Andrews D.W. et al. 1987). 
In human cells YRNA, another PolIII transcript, associates with Ro60 and La 
protein to build the Ro RNPs. (122. Fabini et al. 2001). It has been observed that 
Ro RNPs are associated with chromosomal DNA replication and are required for 
DNA replication in human cells.  (123.  Christov C.P. 2006). In addition, PolIII is 
responsible for H1 RNA production which represents the RNA subunit of RNase 
P, a processing ribonucleoprotein involved in maturation of tRNA precursors.  
(124. Kikovska E. et al 2007). However, there are a number of other RNA 
encoding genes that are transcribed as precursors and are also processed by RNase 
P. Recently, RNase P from yeast was shown to be involved in a new pathway for 
alternative maturation of intron-encoded box C/D SnoRNAs, which are involved 
in rRNA covalent modification. ( 125. Coughlin D.J. et al. 2008).  
Additional indications that nuclear RNase P can bind and cleave non-tRNA-like 
substrates in a sequence specific fashion come from studies that show the possible 
involvement of RNase P in pre-rRNA processing. (126. Niranjanakumari S. et al. 
2007). RNAse P seems to be involved in the recognition of cleavage sites near an 
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apparent sequence consensus in the ITS1 region of rRNA precursor, although 
multiple minor cleavage sites were also identified. (127. Chamberlain J.R. 1996).  
Given the non-random association of mRNAs with RNase P and effects on the 
abundance of these RNAs by RNase P mutants, it appears that RNase P could be 
involved in mRNA turnover, as well as tRNA, snoRNA and rRNA maturation.  
RNA Polymerase III is also responsible for the transcription of U6, the small 
nuclear RNA component U6 snRNP, a component of the spliceosome machinery. 
(128. Kunel G. et al. 1986). Finally one of the most characterized target of PolIII 
is the rRNA 5S. 5S rRNA is known as the only rRNA that is transcribed out of the 
nucleolus and is not matured after 47S processing. It has been shown that after 
transcription, rRNA 5S shuttle in the cytoplasm and form a complex with RPL5. 
Subsequently 5SrRNA can be transported to the nucleus where, within RPL5 and 
RPL11 is incorporated in the large subunit processome during early steps of 
ribosome biogenesis. The 5S rRNA represents an essential component of 60S 
subunit and may exert a crucial role in ribosome production. In addition different 
evidence lead to the postulation that 5S rRNA RPL5 and RPL11 represent the 
pivotal  players involved in MDM2 inhibition after ribosome biogenesis 
alteration. RNA polymerase III products are involved in housekeeping cellular 
processes such as protein synthesis (tRNA), ribosome assembly (5S rRNA) and 
rRNA processing (RNase P and MRP), and deregulation of these essential ncRNA 
could potentially results in ribosome biogenesis stress. 
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Results 
3.1 POLR3A interference leads to inhibition of 
RNA Polymerase III activity 
 
To inhibit in a selective manner the activity of RNA Polymerase III (Pol III) we 
deplete a catalytic subunit of the enzyme, the POLR3A, by transfection of small 
interfering RNA oligonucleotides (siRNA) in HCT116 and U2OS human cancer 
cells. We evaluate the residual expression of POLR3A mRNA by RT-real time 
PCR after 48H from the end of transfection procedure and observed a reduction of 
about 80% of analyzed mRNA respect to control cells transfected with non-
silencing oligonucleotides (NS) (FIG 1A). In order to evaluate the transcriptional 
activity of RNA Polymerase III, we evaluated the expression of tRNAs and 5S 
rRNA. Since tRNAs are characterized by a long half-life, it was necessary to 
evaluate the expression of tRNA precursors after POLR3A interference, to obtain 
information about Pol III transcriptional activity. For this reason we performed a 
RT Real Time qPCR using a methodological approach that permits to evaluate 
only the amount of new synthetized tRNAs. We found that the treatment with 
POLR3A siRNA leads to a decrease in the level of POLR3A mRNA and a 
reduction of tRNAs precursors expression (FIG3.1A). Regarding the evaluation of 
5S rRNA expression, 5S rRNA is present in every 60S subunit of the cell 
ribosomes and therefore characterized by a very long stability, thus also in this 
case was necessary to analyze the amount of the new synthesized rRNA. For this 
purpose, we incorporated in HCT116 human tumor cells, transfected with 
POLR3A siRNA, a radioactive analog of Uridine: the 
3
H-Uridine. We performed 
a pulse of 
3
H-Uridine for 1H and harvest the cells after different time of chase 
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with unlabeled Uridine. After the treatment, we extracted the total RNA and 
evaluated the production of newly synthetized small RNAs by autoradiography.  
The autoradiographic analysis showed, 48 hours after the end of POLR3A siRNA 
transfection, a strong reduction of newly synthetized 5S rRNA (FIG.3.1B). These 
preliminary results indicated that targeting POLR3A expression by RNA 
interference represents a good method to inhibit Pol3 mediated transcription. 
 
FIG. 3.1: 
 
FIG.3.1: POLR3A siRNA transfection lead to an inhibition of PolIII transcriptional activity 
A) RT Real Time qPCR analysis of POLR3A mRNA and tRNA precursors in HCT116 and 
U2OS human tumor cell after POLR3A interference. B) Autoradiographic analysis of 
3
HUridine 
labeled small RNAs in HCT116 tumor cells after POLR3A inhibition. 
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3.2 RNA Polymerase III inhibition causes nucleolar 
fragmentation and affects rRNA maturation 
RNA Polymerase III products, such as 5S rRNA, are involved in ribosome 
biogenesis, thus the inhibition of Pol3 activity should result in an altered 
production of mature ribosomes. As reported above, the nucleolus represents the 
organelle where ribosome biogenesis takes place and changes in ribosome 
biogenesis give rise to disruption of the nucleolar structural organization. Since 
the nucleolar morphology can be very easily evaluated at light microscopical level 
by the AgNOR staining, we analyzed the nucleolar morphology in HCT116 and 
U2OS human tumor cells, 48 hours after PolIII inhibition, using this staining 
procedure. We found that the AgNOR-stained dots were no longer clustered 
within the nucleolar body, but are irregularly distributed throughout the 
nucleoplasm, thus giving rise to the so called nucleolar fragmentation. (FIG. 3.2 
A) In order to evaluate of the changes in production of the mature ribosome 
subunits we conducted the analysis of the polysome profile in POLR3A depleted 
HCT116 cells. This analysis clearly shows that 48 hours after the end of POLR3A 
interference a decrease of the 60S and 80S subunits was present. Interestingly the 
fraction of polysomes-associated RNA is not affected, indicating that, at this time 
point, the 60S subunit production is impaired, but the protein synthesis was 
unaffected. Another more informative evaluation about the status of the ribosome 
production is represented by the analysis of the maturation of the rRNA. Since 
rRNA processing is a multistep mechanism that lead to the production of a series 
of intermediates rRNA, we performed a pulse and chase analysis experiment 
followed by autoradiography to evaluate the amount of the different species of 
rRNA.  
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FIG. 3.2 
             
FIG. 3.2: Pol III inhibition cause nucleolar fragmentation and affects rRNA processing 
     A)AgNor staining of U2OS and HCT116 cells. B) Ribosome profile analysis of 
            HCT116cells.Pol III inhibition lead to a decrease in 60S and 80S subunit production. 
                 C) Autoradiographic analysis of Pulse Chase 
3
H-Uridine labeled small RNAs of HCT116 
after POLR3A interference. 
 
 
                    
The autoradiographic analysis shows that 1 hour after 
3
H-Uridine incorporation, a 
progressive reduction of the 28S rRNA maturation in Pol III inhibited cells was 
found together with an evident accumulation of 32S rRNA in comparison with 
control cells. On the contrary the production of rRNA 18S was unaffected. This 
analysis suggested that Pol III inhibition caused a selective inhibition of 32S 
rRNA precursor maturation, which correlated with the reduction of the mature 
60S subunit production observed by polysome profile analysis. These data lead to 
the conclusion that in our experimental model RNA Polymerase III activity was 
required for a correct maturation of rRNA and, mainly, for the assembly of the 
60S subunit.  
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3.3 The ribosomal stress and nucleolar disruption induced 
by RNA Polymerase III inhibition did not activate the p53 
pathway 
There is evidence that ribosomal stress associated with nucleolar disruption 
induces p53 stabilization by the activation of the RP-p53-MDM2 pathway. Thus 
we verify whether also in the case of Pol III inhibition, p53 stabilization occurred. 
We evaluated the status of p53 pathway by western blot, immunocytochemistry 
and RT Real time qPCR. Unexpectedly, in HCT116 and U2OS cells, Pol III 
inhibition did not lead to any increase of p53 expression and activity, despite the 
evident alteration of ribosome biogenesis and nucleolar disruption. Interestingly, a 
slightly reduction of p53 protein was even observed (FIG.3.3 A and 3.3 B).The 
mRNA levels of p53 target genes appeared to be not modified after PolIII 
inhibition (FIG.3.3 C). On the other hand, POLR IIIA depletion also affected the 
stabilization of p53 and the expression of its target genes, under rRNA 
transcription inhibition induced either by low dose Act D treatment or POLRIA 
interference, as shown by Western blot and immunocytochemistry analysis 
(FIG.3.3 A and 3.3 B). This data demonstrated that the POLR3A interference lead 
to impaired ribosome biogenesis as well as nucleolar disruption without activating 
the p53 mediated response.  
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FIG.3.3: PolIII inhibition do not correlates with p53 stabilization A) Western blot analysis of p53, 
MDM2 and P21 expression after siPOLR3A transfection in HCT116 and U2OS cells. P53 and its 
target do not stabilize after Pol III inhibition. B) Immunocytochemystry of p53 in HCT cells after  
Pol III inhibiiton and low dose  ACTD treatment. D)  Evaluation of mRNA expression of 
POLR3A and POLR1A after siRNA transfection in all the experimental conditions. 
 
HCT116 U2OS 
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3.4 RNA Polymerase III inhibition leads to a p53 
independent cell cycle arrest 
 
Since hindered ribosome biogenesis inhibits cell proliferation, we evaluate the cell 
number after POLRIIIA interference by Cristal Violet staining of HCT116 and 
U2OS cells. As expected, we found that PolIII inhibition caused a reduction of 
cell proliferating activity. However, we also found that PolIII inhibition lead to a 
reduction of cell proliferation rate also in HCT116 which express a dominant 
negative form of p53 (HCT116 p53DD), therefore indicating that the effect on cell 
cycle progression was p53 independent (FIG.3.4).    
FIG. 3.4 
        
FIG. 3.4: Graphic representation of crystal violet stained HCT116, U2OS, HCT 116 pBABE and 
HCT116 p53DD cells after 48h, 72h and 96h from transfection of POLR3A siRNA. Cell number 
was evaluated by spectrophotometric measurement of stained cells which is represented with 
relative optic density 
50 
 
3.5 TF3A interference led to a specific inhibition of 5S 
rRNA transcription 
The reason for the absence of p53 stabilization after RNA polymerase III 
inhibition could be dependent on a molecular paradox. Recently, it was suggested 
that the 5S rRNA is involved in MDM2 inhibition together with RPL5 and 
RPL11. Thus Pol III inhibition lead to ribosome biogenesis alteration which 
potentially can activate p53 pathway, but in this particular case, the lack of one of 
the regulators of the stress response, the 5S rRNA, could affect the efficient 
inhibition of MDM2 and consequently the stabilization of p53. To verify this 
hypothesis we specifically inhibit the production of 5S rRNA and analyzed the 
effects on nucleolar morphology, ribosome biogenesis status, cell cycle 
progression and the p53 pathway. To specifically reduce the production of 5S 
rRNA, we depleted, by RNA interference, a transcription factor required for 
 Pol III recruitment on 5S rRNA promoters, known as TF3A. First of all, we 
verified the efficiency of RNA interference by RT Real Time qPCR, and observed 
that a 48 hours after  the end of TF3A siRNA transfection a reduction of more 
than the 90% of TF3A mRNA was present in HCT116 and U2OS cells (FIG. 5A).  
To ascertain whether TF3A interference lead to a specific reduction of 5S rRNA 
production we performed a pulse chase experiment by 1 hours of  incorporation of 
labeled 
3
H Uridine and harvested the cells after different time points. The 
autoradiography analysis of small RNAs demonstrated that 72 hours after TF3A 
interference there was a significant reduction of new synthetized 5S rRNA, while 
the production of tRNA was not modified (FIG.3.5 B).   
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FIG. 3.5: 
 
FIG. 3.5: TF3A siRNA transfection leads to a specific inhibition of 5S rRNA production 
A)RT Real Time qPCR analysis of TF3A mRNA in HCT116 and U2OS 
human tumor cell after TF3A interference. B) Autoradiographic analysis of 
3
HUridine 
labeled small RNAs in HCT116 tumor cells after 48h and 72h of TF3A interference. 
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3.6 The lack of 5S rRNA is linked with an altered 
ribosome rRNA processing 
First, we investigated whether 5S rRNA depletion affected ribosome biogenesis. 
We analyzed the nucleolar morphology of HCT116 and U2OS cells after 
transfection of TF3A siRNA by AgNOR staining. 72 hours after the end of TF3A 
siRNA transfection, no nucleolar alterations were found (FIG. 3.6A). Then we 
analyzed by biochemical tests the status of ribosome biogenesis. The evaluation of 
rRNA maturation with pulse chase autoradiographic analysis showed that 72H 
after TF3A siRNA transfection a strong accumulation of 32S rRNA precursors 
was evident, and the production of 28S rRNA strongly reduced. There was no 
difference in 18S rRNA production thus indicating that the lack of 5S rRNA 
specifically inhibited the maturation of 60S pre-ribosomal particle (FIG. 3.6B). 
 
FIG. 3.6: 
               
FIG. 3.6: 5S rRNA depletion affects rRNA processing A)AgNor staining of U2OS and HCT116 
cells B) Autoradiographic analysis of Pulse Chase 
3
H-Uridine labeled small RNAs of HCT116 
after TF3A interference 
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3.7 5S rRNA depletion did not activate p53 pathway 
 
These findings demonstrated that after 5S rRNA depletion changes in rRNA 
maturation occurred which were superimposable to those found after Pol III 
inhibition. Thus, we analyze again the status of p53 pathway in HCT116 and 
U2OS cells 48 and 72 hours after the end of TF3A siRNA transfection procedure. 
Western blot analysis of p53, p21 and MDM2 protein levels showed that 5S 
rRNA depletion did not stabilize p53. In addition, in cells silenced for TF3A, p53 
was less efficiently stabilized after the inhibition of rRNA transcription induced 
either by ACTD treatment or Pol I inhibition, as shown by western blot and 
immunocytochemistry analysis (FIG. 3.7A and 3.7 B). Moreover the evaluation of 
mRNA expression of p53 target genes 48 hours after TF3A siRNA transfection, 
showed no significant increases in p21, BAX and PUMA expression (FIG.3.7C).  
 
3.8 TF3A inhibition caused a p53 independent cell cycle 
arrest 
Finally we want to verify whether the reduction in cell number was present after 
rRNA 5S depletion. We performed a Crystal Violet assay on HCT116, U2OS, 
HCT116 pBABE and HCT116 p53DD and evaluated the cell number at 48, 72 
and 96 hours from the end of TF3A siRNA transfection procedure. 5S rRNA 
depletion affected the proliferation rate both in cells with a wild type p53 
(HCT116 and U2OS) and in cells expressing a dominant negative form of the 
tumor suppressor (HCT116 p53 DD) in comparison with control cells (FIG. 3.8). 
This led to the conclusion that 5S rRNA depletion caused a p53 independent 
reduction of cell proliferation rate.    
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 FIG. 3.7: 
                               
             
                    
        
    
FIG. 3.7: TF3A inhibition do not correlates with p53 stabilization A)Western blot analysis of p53, 
MDM2 and P21 expression after TF3A siRNA transfection in HCT116 and U2OS cells. P53 and 
its target do not stabilize after TF3A inhibition. B) Immunocytochemystry of p53 in HCT cells 
after  polIII inhibiiton and low dose  ACTD treatment. D)  Evaluation of mRNA expression of 
TF3A after POLR1A and TFIIIA siRNA transfection even in co 
 
55 
 
FIG. 3.8 
 
FIG. 3.8: Graphic representation of crystal violet stained HCT116, U2OS, HCT 116 pBABE and 
HCT116 p53DD cells after 48h, 72h and 96h from transfection of TF3A siRNA. Cell number was 
evaluated by spectrophotometric measurement of stained cells which is represented with relative 
optic density 
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Discussion 
This study demonstrated that the inhibition of either Pol3 whole transcription or 
the single depletion of one of its target, the 5S rRNA, led to an altered ribosome 
biogenesis and to inhibition of cell cycle progression, without the activation of the 
p53 pathway. In detail, Pol3 inhibition and rRNA 5S specific depletion induced 
similar changes in ribosome biogenesis. In fact, both treatments cause an 
accumulation of 32S rRNA precursor with a reduction of 28 and 5.8 S rRNAs, 
without modify the 18S rRNA maturation. Therefore, POLR3A and TF3A 
interferences hindered the processing of 60S pre-ribosomal particle without 
affecting the 40S ribosome subunit production. Unexpectedly Pol3 inhibition and 
5S rRNA depletion, despite the induction of ribosome biogenesis alteration, do 
not activate the p53 pathway. Even more interestingly, we found that the 
inhibition of Pol III activity, but not the depletion of 5S rRNA, caused a strong 
alteration of nucleolar morphology, described as nucleolar fragmentation. 
Consequently it is possible that other Pol III targets, respect to 5S rRNA, can be 
necessary for nucleolar integrity. Nucleolar disruption was considered the 
“conditio sine qua non” for p53 stabilization after ribosome biogenesis alteration 
(105. Rubbi and Milner 2002).  According to these authors the “disruption of the 
nucleolus mediates stabilization of p53 in response to DNA damage and other 
stresses”. The mechanism proposed was the following: in order to stabilize p53 
every cellular stress should disrupt the nucleolus in order to allow the ribosome 
proteins to be released in the nucleoplasm where they inhibit the MDM2 function. 
This widely accepted model for p53 stabilization was, however, contested in a 
recent study in which it has been demonstrated that the inhibition of 45S 
transcription, by POLR1A depletion, led to p53 stabilization without affecting the 
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nucleolar integrity (106. Donati el al. 2010). According to these data, after 45S 
rRNA precursor transcription inhibition, newly synthetized ribosomal proteins, no 
more required for rRNA binding, are more available for MDM2 inhibition. For 
this reason it was proposed that changes in ribosomal protein equilibrium between 
rRNA and MDM2 after ribosome biogenesis alterations exerted a pivotal role in 
p53 stabilization, rather than the shuttling of ribosomal protein in the nucleoplasm 
after nucleolar disruption. The results showed in the present study are consistent 
with absolute independence of the nucleolar integrity of p53 stabilization. In fact, 
in our experimental system, the inhibition of Pol III activity led to an impairment 
of ribosome biogenesis and nucleolar disruption in absence of p53 stabilization. 
Moreover, transfection of POLR3A or TF3A siRNA not only affect p53 
stabilization but in general causes a slightly reduction of P53 protein levels. The 
absence of p53 stabilization could be explained by recent findings which strongly 
suggest an involvement of 5S rRNA in p53 regulation. It was shown that RPL5 
and RPL11 are limiting for MDM2 inhibition more than other ribosomal proteins, 
and recent studies also show that RPL5, RPL11 and 5S rRNA are able to bind 
MDM2 (109. Horn H.F., Vousden K.H. 2008). In addition, RPL11, RPL5 and 
rRNA5S are present in the same complex in the 60S mature ribosome subunit  
(83. Zhang et al., 2007) and this strongly support the idea that the three factors can 
exert their extraribosomal functions by acting in a ternary complex. Inhibition of 
RNA Polymerase III activity reduced the level of 5S rRNA and could affect the 
function of the inhibitory complex of MDM2, leading to a deregulation of the 
normal homeostatic control of p53 levels. To further demonstrate the hypothesis 
that 5S rRNA is essential for MDM2 regulation in our experimental conditions, it 
will be necessary to evaluate the amount of RPL11 or RPL5 binding to MDM2 
with a co-immunoprecipitation assay and Western blot analysis after Pol III 
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inhibition or 5S rRNA depletion. This experimental approach will give us more 
detailed evidences of the proposed model which is here described by a graphical 
representation (FIG. 4.1). Finally, we demonstrated that Pol III inhibition and 5S 
rRNA depletion were responsible for a strong reduction of cell proliferation rate, 
in a p53 independent manner. Actually, we don’t know the molecular mechanism 
responsible for this cell cycle progression inhibition, but further biochemical 
analysis will be performed to better understanding the basis of such reduction in 
cell number. Recently, it has been proposed that inhibition of ribosome biogenesis 
can be used as a therapeutic strategy for cancer treatment. By using a new small 
molecule (CX-5461) to specifically inhibit RNA polymerase I transcription, it was 
found that cells characterized by a high rRNA transcription rate such as B-
lymphoma cells underwent to a rapid apoptotic p53-dependent death at difference 
of normal lymphocytes, both in vitro and in vivo. (129. Bywater M.J., 2012).    
Our findings, indicating that the selective inhibition of RNA Polymerase III 
transcription negatively affected the proliferation rates also in cells lacking a 
functional p53, may suggest that targeting RNA polymerase III can be an new 
therapeutic strategy to threat tumors characterized by loss of p53 function, which 
represent about the fifty per cent of all malignancies.  
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FIG. 4.1: 
 
 
FIG.4.1: Schematic representation of the model proposed in this study. In normal growing 
conditions 5S rRNA is transcribed by Pol III, exported to the cytoplasm, where interact with 
RPL5, and transported to the nucleolus with others ribosomal proteins. RPL11, 5SrRNA and RPL5 
are incorporated in the 90S pre-ribosomal particle and participate to 60S subunit production. The 
ternary complex could be in continuous equilibrium, with the other ribosomal proteins, between 
rRNA and MDM2 binding, providing a constant p53 level modulation. After pol3 inhibition, 5S 
rRNA is no more produced and this led to a defective rRNA processing, a strong accumulation of 
32S rRNA precursor and to impaired 60S subunit production. In parallel, the function of the 
MDM2 inhibitory complex could be affected by the lack of 5SrRNA and the ineffective inhibition 
of MDM2 can be responsible for the reduction of p53 protein level and for the reduced 
stabilization after the others induced ribosome biogenesis stresses. Blue spots represent large 
subunit ribosomal proteins, while red spots represent small subunit ribosomal proteins. Large 
subunit ribosomal proteins L5 and L11 are in evidence 
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Materials and methods: 
5.1 Cell lines, culture conditions and drug treatments 
U2OS and HCT116 human cancer-derived cell lines were cultured in monolayer 
at 37°C in humidified atmosphere containing 5% CO2 in Dulbecco’s modied 
Eagle’s medium (Euroclone, Milan,Italy) supplemented with 10% foetal bovine 
serum (FBS, Sigma). Actinomycin D (Biovision, Mountain View, CA, USA) was 
used at a final concentration of 5 nM for 6 hours.  
 
5.2 RNAi, plasmids and transfection reagents 
Custom Sigma siRNA (Invitrogen, Carlsbad, UK) targeted against catalytic 
subunit of RNA Polymerase III (POLRIIIA) or RNA Polymerase I (POLRIA) and 
siRNA against TFIIIA were used, whereas a non-silencing siRNA was used to 
transfect controls. Cells were transfected with lipofectamine RNAiMAX 
(Invitrogen) in opti-MEM medium (Invitrogen), accordingly to manufacturer’s 
procedures. The sequences of the transfected siRNA are listed below (Table 5.1) 
Table 5.1 
             
SiRNA  
5’- 3’ Sequences 
 
NS 
GCAUCAGUGUCACGUAAUA 
POLR3A CAAGUAUGGUGACAUCGUA 
 
POLR1A           CAACUACGAGGUGAUAAUGAA 
TF3A CACUAGGCAUGCUGUUGUA 
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5.3 AgNOR staining 
HCT116 and U2OS cells were grown on coverslip and transfected with 
POLRIIIA or TFIIIA siRNA. After the treatments the cells were washed in PBS, 
fixed, and permeabilized for 4 min with 2% paraformaldehyde added with 1% 
Triton X-100 diluted in PBS. Fixed cells were then washed three times in H2Od 
and then stained with 2% Silver Nitrate (AgNO3) solution for 13 minutes at 37°C. 
The reaction was blocked with H2Od and stained cells are dehydrated and 
mounted on microscope slides with Canada balsam. Samples were observed under 
a light microscope. 
 
5.4 RNA extraction, reverse transcription 
and real-time PCR 
Cells were harvested and total RNA extracted with TRI reagent (Ambion, Austin, 
TX, USA), according to manufacturer instructions. Whole cell RNA was 
quantified spectrophotometrically and 1 mg of RNA for each sample were treated 
with DNAse and reverse transcribed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA), following the 
manufacturer’s protocol. The relative amounts of POLR3A, pre-tRNA Leu, pre-
tRNA Tyr, POLR1A, TF3A, p21, BAX, PUMA,  β-glucuronidase and  β-Actin 
were evaluated by real-time PCR performed on an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems) or Light Cycler 480 (Roche), with the 
2_DDCT method (Livak and Schmittgen, 2001). The mean DCT value of the 
control sample was used in each experiment to calculate the DDCT value of 
sample replicates. Primers for SYBR Green real-time PCR analysis of human 
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POLR3A, pre-tRNA Leu, pre-tRNA Tyr and have been already described Shor B. 
et al. (J. Biol. Chem., 2010), while primers for POLR1A,  p21, BAX,  PUMA and 
the internal controls β-glucuronidase or β-Actin mRNAs were quantified with 
TaQMan Gene Expression Assays primers and probe kits (Applied Biosystems). 
Primer sequences, for SYBR green based real time qPCR, used in this work are 
following listed (Table 5.2).  
 
Table 5.2 
Primer 5’- 3’ Sequences 
 
POLR3A 
FW 
CCACCGCCTACAATCCTAAA 
POLR3A 
RV 
TAGGGTTCCTTTGTCCATGC 
Pre-RNA 
Leu FW 
ATG GCC GAG TGG TCT AAG G 
Pre-RNA 
Leu RV 
ACC AGA AGA CCC GAA CAC AG 
Pre-RNA 
Tyr FW 
CCT TCG ATA GCT CAG CTG GT 
Pre-RNA 
Tyr RV 
CGACCTAAGGATGTCCACAAAT 
TF3A 
FW 
  TTGTGTGTGAACATGCTGGCTGTG 
TF3A 
RV 
 TGAGATGAGAGGCCAAACTCCGTT 
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5.5 Analysis of newly synthesized rRNA with 
3
H-Uridine 
labeling 
 
For 18S and 28S rRNA processing analysis or evaluation of newly synthesized 5S 
rRNA and tRNAs, pulse-chase labeling was performed. In brief, 48 or 72 hours 
after transfection of chemically synthesized siRNA, HCT116 cells were incubated 
in medium containing 2,5 μCi/mL of 3H-Uridine for 1 hour (indicated as Pulse). 
Cells were then changed to medium containing non-radioactive Uridine at the 
concentration of 1mM and harvested at different time points (here described as 
Chase).  Total RNA was isolated with  Tri reagent and the extracted RNA was 
quantified by spectrophotometric analysis and the radioactivity incorporation was 
evaluated with β-Counter analysis. Equal amount of 3H-Uridine labeled RNAs 
were resolved in Formammide/Formaldehyde loading Dye by 1% agarose–
formaldehyde gel (in 1X MOPS/6% Formaldehyde running buffer) for 18S and 
28S rRNA processing analysis and by 10% polyacrylamide, TBE, 7M Urea Gel 
(in TBE 0,5X running buffer) for small RNA production analysis. Labeled RNA 
was then transferred on Hybond N+ membrane (GE Healthcare) by semidry 
transfer in TBE 0,5X for small rRNAs or by backward capillarity transfer in 20X 
SSC for 18S and 28S evaluation. RNAs were UV-crosslinked to the membrane by 
Stratalinker® UV Crosslinker and the membranes are treated with EN
3HANCE™ 
Spray Surface Autoradiography Enhancer (Perkin Elmer). Finally, for labeled 
RNAs autoradiographic detection, the membranes were exposed for 6 days at -
80°C on ECL Amersham Hyperfilms (GE Health Care). 
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5.6 Polysome profile 
48 hours after the end of POLR3A siRNA transfection, HCT116 cells were 
washed in cold phosphate-buffered saline (PBS) at 4°C and then  lysed with 1,5 
mM KCl, 2,5 mM MgCl2, 5,0 mMTris PH 7.4, 1% Triton x-100, 1% Sodium 
Deoxycholate, 100mg/ml Cicloexhimide, 100 U.E./ml Rnase OUT (Roche) and 
protease inhibitor cocktail (Roche). The lysates were then centrifuged at 14 000 g 
for 10 min at 4 1C and the supernatant was used for the polysome profile analysis. 
Lysates were stratified onto a 10–50% sucrose gradient in 300 mM NaCl, 100 
mM MgCl2, 100 mM Tris PH 7.4, 100 mM Dithiothreitol (DTT) and centrifuged 
at 4°C for 1,5 h at 32000g. From gradients, 14 fractions were collected by a 
gradient profiler station, their absorbance was read at 260 nm and graphically 
analyzed by the gradient profiler software. 
 
5.7 Western blotting 
After the treatments, HCT116 and U2OS cells were washed with ice-cold PBS 
and lysed in 50 mM Tris-HCl pH 8, 250 mM NaCl, 1% Triton X-100, 0.25% 
Sodium Deoxycholate, 0.05% SDS, 1 mM Dithiothreitol (DTT) and protease 
inhibitior cocktail (Roche). The lysates were centrifuged at 14000 g for 10 min at 
4°C and the supernatant was used for the western blot analysis. After 
spectrophotometric quantification with the Bio-Rad Protein Assay (Bio-Rad 
Laboratories, Hempstead, UK), an equal amount of proteins were resolved in 
NuPAGE Novex Midi Gels (Life Tecnologies) and transferred to nitrocellulose 
membranes (GE healthcare) by semi-dry transfer. Immobilized proteins were 
blotted overnight at 4°C with the indicated primary antibody. Horseradish 
peroxidase-conjugated secondary antibody, from Santa Cruz Biotechnology (CA, 
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USA), were used. Detection was performed by ECL detection system (GE 
healthcare) and membranes were exposed to ECL Amersham Hyperfilms (GE 
Health Care). The antibodies used for western blot analysis are the following: 
rabbit polyclonal α-p53 (FL-393, Santa Cruz), mouse monoclonal α-p21 (SXM30, 
BD Pharmigen),  mouse monoclonal α-MDM2 (SMP14, Santa Cruz) mouse 
monoclonal α-β-Actin (C-2, Santa Cruz).   
 
5.8 Immunocytochemistry 
The expression of p53 was also evaluated by immunocytochemical analysis in 
HCT116 cells. 48 hours or 72 hours, respectively after the end of POLR3A or 
TF3A siRNA transfection, cells grown on coverslips were first washed in PBS, 
fixed, and permeabilized for 10 min with 2% paraformaldehyde, with 1% Triton 
X-100 diluted in PBS, and incubated with mouse monoclonal α-p53 antibody 
(BP53-12, Novocastra Laboratories Ltd.,) in PBS containing 1% bovine serum 
albumin and processed by novolink polymer detection system (Novocastra 
Laboratories Ltd.), according to the manufacture’s protocol. Finally, stained cells 
are dehydrated, mounted on microscope slides with Canada balsam and observed 
under a light microscope 
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5.9 Cristal Violet Staining 
To evaluate cell proliferation rates on HCT116, HCT116 pBABE, HCT116 
p53DD or U2OS cells transfected with POLRIIIA or TFIIIA siRNA, we stained 
the cells with crystal violet. Briefly, cells were washed twice with PBS and then 
fixed in formalin. The same treatment was used for each analyzed time point (48, 
72 and 96 hours). Fixed cells were washed three times with H2Od and stained 
with 0,1% crystal violet solution in 20% Met OH for 30 minutes in agitation at 
room temperature. After four washes in H2Od, cells were completely dried and 
the bounded crystal violet was solubilized in 10% acetic acid for 30 minutes in 
agitation at room temperature. Finally, the solubilized crystal violet solution was 
collected and the relative absorbance was measured spectrophotometrically at 595 
nm. Each point of the growth curve obtained was analyzed in triplicate.   
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